So I have been watching or rather, set a google alert for "androgen inhibitor", and occasionally come across interesting articles mainly in the prostate cancer field.
IF I am not mistaken, Kintor is doing something similar? Could this perhaps be a change?
IF I am not mistaken, Kintor is doing something similar? Could this perhaps be a change?
FDA Updates Darolutamide Label for Prostate Cancer
The FDA has approved a supplemental new drug application to add overall survival (OS) and other secondary end point data from the phase 3 ARAMIS trial (NCT02200614) to the prescribing information for darolutamide (Nubeqa) for the treatment of patients with nonmetastatic prostate cancer (nmCRPC).
www.oncnursingnews.com